Welcome to our dedicated page for INCYTE SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Pablo J. Cagnoni, President and Global Head of R&D at Incyte, reported selling 10,640 shares of common stock on August 5, 2026 at $122.69 per share in a code S open-market or private transaction executed under a Rule 10b5-1 trading plan. Following the sale, he reports ownership of 204,804 shares, including 183,200 shares issuable from previously reported, unvested restricted stock units and earned performance stock units.
INCYTE CORP EVP & Chief Scientific Officer Patrick A. Mayes exercised employee stock options covering 2,207 shares at $106.47 on August 5, 2026, then sold 2,207 common shares at $123.99 per share under a Rule 10b5-1 trading plan.
Footnotes state the option award was fully vested and exercisable as of that date and note 59,537 shares of common stock issuable from previously reported restricted stock units that have not vested.
Incyte Corporation affiliate Pablo Cagnoni filed a Form 144 indicating an intention to sell up to 10,640 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a stated aggregate market value of $1,305,450.33 as of the filing.
The filing also notes that these shares were acquired on June 1, 2026 as restricted stock and performance shares from the issuer, and discloses that 15,888 shares of common stock were sold on July 31, 2026 for $1,901,833.32 during the prior three months. Shares outstanding are listed as 202,697,746.
Patrick A. Mayes filed a Form 144 notice to sell up to 2,207 shares of INCY common stock, to be delivered through a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing also reports prior sales of INCY common shares in the last three months, including 6,055 shares on 08/03/2026 for $729,203.65 and 41,899 shares on 07/31/2026 for $5,005,186.06.
Incyte Corp executive Pablo J. Cagnoni, President and Global Head of R&D, reported selling 15,888 shares of common stock on 2026-07-31 at $119.70 per share in an open market or private transaction. After the sale, he directly holds 215,444 shares, including 183,200 shares issuable from previously reported restricted stock units and earned performance stock units that have not vested. The transaction was made under a Rule 10b5-1 trading plan.
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte, exercised employee stock options covering 45,767 shares and acquired common stock, then reported sale transactions totaling 47,954 shares of common stock on July 31 and August 3, 2026, pursuant to a Rule 10b5-1 trading plan.
The exercised options included grants with exercise prices of $61.18, $72.27 and $105.43 per share. Footnotes state his reported holdings also include 59,537 additional shares underlying unvested restricted stock units.
Patrick A. Mayes filed to sell common stock of Incyte Corporation through Morgan Stanley Smith Barney LLC. The planned transaction covers 6,055 shares of common stock, related to a stock option exercise, with an aggregate market value of $729,203.65 as of the filing. The shares are listed on NASDAQ and the transaction date is August 3, 2026. During the prior three months, Mayes also sold 41,899 shares of common stock for an aggregate value of $5,005,186.06 on July 31, 2026.
Incyte Corporation is registering a planned resale of common stock under Rule 144. The filing covers 41,899 common shares, with an aggregate market value of 5,005,186.06, proposed to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ on or after July 31, 2026. The shares include 39,712 shares acquired from the issuer via stock option exercises for cash on July 31, 2026 and 2,187 shares acquired as restricted stock from the issuer on July 15, 2026.
A shareholder of Incyte Corporation (INCY) has filed to potentially sell 15,888 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale, with an aggregate market value of $1,901,833.32, is listed for NASDAQ with an anticipated sale date of 07/31/2026. The securities include 12,181 restricted stock shares dated 07/14/2024 and 3,707 performance shares dated 07/14/2026.
Incyte Corporation reported strong profitability for the three and six months ended June 30, 2026. Total revenues were $1,674,039 (in thousands) for the quarter and $2,946,715 (in thousands) for the first half of 2026, compared with $1,215,529 and $2,268,427 (in thousands) in 2025.
Growth was driven by higher net product sales of $2,592,633 (in thousands), including JAKAFI net sales of $1,574,414 (in thousands) and OPZELURA net sales of $592,751 (in thousands). OPZELURA results include a one-time, non-cash $246.0 million benefit from reversing Medicaid rebate accruals following a settlement with CMS. Product royalty revenues also increased to $325,882 (in thousands).
Net income rose to $585,605 (in thousands) for Q2 and $888,935 (in thousands) for the first half, with diluted EPS of $2.81 and $4.28, respectively. The effective tax rate declined to 18.8% for the six-month period, helped by tax credits, foreign tax effects and U.S. tax law changes. Incyte ended June 30, 2026 with cash and cash equivalents of $3,982,375 (in thousands) and generated operating cash flow of $877,013 (in thousands). Subsequent to quarter-end, it agreed to acquire Vega Therapeutics for $1.25 billion in cash plus up to $750.0 million in sales milestones, which it expects to expense largely as in-process R&D in the third quarter of 2026.